Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1991 Jan;46(1):9–14. doi: 10.1136/thx.46.1.9

The protective effect of a beta 2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease.

E H Bel 1, A H Zwinderman 1, M C Timmers 1, J H Dijkman 1, P J Sterk 1
PMCID: PMC1020906  PMID: 1871705

Abstract

Beta 2 agonists reduce airway hypersensitivity to bronchoconstrictor stimuli acutely in patients with asthma and chronic obstructive lung disease. To determine whether these drugs also protect against excessive airway narrowing, the effect of inhaled salbutamol on the position and shape of the dose-response curves for histamine or methacholine was investigated in 12 patients with asthma and 11 with chronic obstructive lung disease. After pretreatment with salbutamol (200 or 400 micrograms) or placebo in a double blind manner dose-response curves for inhaled histamine and methacholine were obtained by a standard method on six days in random order. Airway sensitivity was defined as the concentration of histamine or methacholine causing a 20% fall in FEV1 (PC20). A maximal response plateau on the log dose-response curve was considered to be present if two or more data points for FEV1 fell within a 5% response range. In the absence of a plateau, the test was continued until a predetermined level of severe bronchoconstriction was reached. Salbutamol caused an acute increase in FEV1 (mean increase 11.5% predicted in asthma, 7.2% in chronic obstructive lung disease), and increase in PC20 (mean 15 fold in asthma, fivefold in chronic obstructive lung disease), and an increase in the slope of the dose-response curves in both groups. In subjects in whom a plateau of FEV1 response could be measured salbutamol did not change the level of the plateau. In subjects without a plateau salbutamol did not lead to the development of a plateau, despite achieving a median FEV1 of 44% predicted in asthma and 39% in chronic obstructive lung disease. These results show that, although beta 2 agonists acutely reduce the airway response to a given strength of bronchoconstrictor stimulus, they do not protect against excessive airflow obstruction if there is exposure to relatively strong stimuli. This, together with the steepening of the dose-response curve, could be a disadvantage of beta 2 agonists in the treatment of moderate and severe asthma or chronic obstructive lung disease.

Full text

PDF
9

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bandouvakis J., Cartier A., Roberts R., Ryan G., Hargreave F. E. The effect of ipratropium and fenoterol on methacholine-histamine-induced bronchoconstriction. Br J Dis Chest. 1981 Jul;75(3):295–305. doi: 10.1016/0007-0971(81)90009-7. [DOI] [PubMed] [Google Scholar]
  2. Bosken C. H., Wiggs B. R., Paré P. D., Hogg J. C. Small airway dimensions in smokers with obstruction to airflow. Am Rev Respir Dis. 1990 Sep;142(3):563–570. doi: 10.1164/ajrccm/142.3.563. [DOI] [PubMed] [Google Scholar]
  3. Britton J., Hanley S. P., Garrett H. V., Hadfield J. W., Tattersfield A. E. Dose related effects of salbutamol and ipratropium bromide on airway calibre and reactivity in subjects with asthma. Thorax. 1988 Apr;43(4):300–305. doi: 10.1136/thx.43.4.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Casterline C. L., Evans R., 3rd, Ward G. W., Jr The effect of atropine and albuterol aerosols on the human bronchial response to histamine. J Allergy Clin Immunol. 1976 Nov;58(5):607–613. doi: 10.1016/0091-6749(76)90207-4. [DOI] [PubMed] [Google Scholar]
  5. Chung K. F., Morgan B., Keyes S. J., Snashall P. D. Histamine dose-response relationships in normal and asthmatic subjects. The importance of starting airway caliber. Am Rev Respir Dis. 1982 Nov;126(5):849–854. doi: 10.1164/arrd.1982.126.5.849. [DOI] [PubMed] [Google Scholar]
  6. Chung K. F., Snashall P. D. Methacholine dose-response curves in normal and asthmatic man: effect of starting conductance and pharmacological antagonism. Clin Sci (Lond) 1984 Jun;66(6):665–673. doi: 10.1042/cs0660665. [DOI] [PubMed] [Google Scholar]
  7. Cockcroft D. W. Airway hyperresponsiveness: therapeutic implications. Ann Allergy. 1987 Dec;59(6):405–414. [PubMed] [Google Scholar]
  8. Cockcroft D. W., Killian D. N., Mellon J. J., Hargreave F. E. Protective effect of drugs on histamine-induced asthma. Thorax. 1977 Aug;32(4):429–437. doi: 10.1136/thx.32.4.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Crane J., Pearce N., Flatt A., Burgess C., Jackson R., Kwong T., Ball M., Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet. 1989 Apr 29;1(8644):917–922. doi: 10.1016/s0140-6736(89)92505-1. [DOI] [PubMed] [Google Scholar]
  10. Dolovich M. B., Sanchis J., Rossman C., Newhouse M. T. Aerosol penetrance: a sensitive index of peripheral airways obstruction. J Appl Physiol. 1976 Mar;40(3):468–471. doi: 10.1152/jappl.1976.40.3.468. [DOI] [PubMed] [Google Scholar]
  11. Du Toit J. I., Woolcock A. J., Salome C. M., Sundrum R., Black J. L. Characteristics of bronchial hyperresponsiveness in smokers with chronic air-flow limitation. Am Rev Respir Dis. 1986 Sep;134(3):498–501. doi: 10.1164/arrd.1986.134.3.498. [DOI] [PubMed] [Google Scholar]
  12. Greenspon L. W., Parrish B. Inhibition of methacholine-induced bronchoconstriction in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1988 Feb;137(2):281–285. doi: 10.1164/ajrccm/137.2.281. [DOI] [PubMed] [Google Scholar]
  13. Gunst S. J., Stropp J. Q., Flavahan N. A. Muscarinic receptor reserve and beta-adrenergic sensitivity in tracheal smooth muscle. J Appl Physiol (1985) 1989 Sep;67(3):1294–1298. doi: 10.1152/jappl.1989.67.3.1294. [DOI] [PubMed] [Google Scholar]
  14. Hargreave F. E., Dolovich J., O'Byrne P. M., Ramsdale E. H., Daniel E. E. The origin of airway hyperresponsiveness. J Allergy Clin Immunol. 1986 Nov;78(5 Pt 1):825–832. doi: 10.1016/0091-6749(86)90226-5. [DOI] [PubMed] [Google Scholar]
  15. Holgate S. T., Beasley R., Twentyman O. P. The pathogenesis and significance of bronchial hyper-responsiveness in airways disease. Clin Sci (Lond) 1987 Dec;73(6):561–572. doi: 10.1042/cs0730561. [DOI] [PubMed] [Google Scholar]
  16. James A. L., Paré P. D., Hogg J. C. The mechanics of airway narrowing in asthma. Am Rev Respir Dis. 1989 Jan;139(1):242–246. doi: 10.1164/ajrccm/139.1.242. [DOI] [PubMed] [Google Scholar]
  17. Laitinen L. A., Laitinen A., Widdicombe J. Effects of inflammatory and other mediators on airway vascular beds. Am Rev Respir Dis. 1987 Jun;135(6 Pt 2):S67–S70. doi: 10.1164/arrd.1987.135.6P2.S67. [DOI] [PubMed] [Google Scholar]
  18. Macklem P. T. The clinical relevance of respiratory muscle research. J. Burns Amberson lecture. Am Rev Respir Dis. 1986 Oct;134(4):812–815. doi: 10.1164/arrd.1986.134.4.812. [DOI] [PubMed] [Google Scholar]
  19. Morell F., Orriols R., Molina C. Usefulness of skin test in Farmer's lung. Chest. 1985 Feb;87(2):202–205. doi: 10.1378/chest.87.2.202. [DOI] [PubMed] [Google Scholar]
  20. Moreno R. H., Hogg J. C., Paré P. D. Mechanics of airway narrowing. Am Rev Respir Dis. 1986 Jun;133(6):1171–1180. doi: 10.1164/arrd.1986.133.6.1171. [DOI] [PubMed] [Google Scholar]
  21. Pride N. B., Taylor R. G., Lim T. K., Joyce H., Watson A. Bronchial hyperresponsiveness as a risk factor for progressive airflow obstruction in smokers. Bull Eur Physiopathol Respir. 1987 Jul-Aug;23(4):369–375. [PubMed] [Google Scholar]
  22. Ramsdell J. W., Nachtwey F. J., Moser K. M. Bronchial hyperreactivity in chronic obstructive bronchitis. Am Rev Respir Dis. 1982 Nov;126(5):829–832. doi: 10.1164/arrd.1982.126.5.829. [DOI] [PubMed] [Google Scholar]
  23. Salome C. M., Schoeffel R. E., Woolcock A. J. Effect of aerosol and oral fenoterol on histamine and methacholine challenge in asthmatic subjects. Thorax. 1981 Aug;36(8):580–584. doi: 10.1136/thx.36.8.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Salome C. M., Schoeffel R. E., Yan K., Woolcock A. J. Effect of aerosol fenoterol on the severity of bronchial hyperreactivity in patients with asthma. Thorax. 1983 Nov;38(11):854–858. doi: 10.1136/thx.38.11.854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sears M. R. Increasing asthma mortality--fact or artifact? J Allergy Clin Immunol. 1988 Dec;82(6):957–960. doi: 10.1016/0091-6749(88)90130-3. [DOI] [PubMed] [Google Scholar]
  26. Sterk P. J., Bel E. H. Bronchial hyperresponsiveness: the need for a distinction between hypersensitivity and excessive airway narrowing. Eur Respir J. 1989 Mar;2(3):267–274. [PubMed] [Google Scholar]
  27. Sterk P. J., Daniel E. E., Zamel N., Hargreave F. E. Limited bronchoconstriction to methacholine using partial flow-volume curves in nonasthmatic subjects. Am Rev Respir Dis. 1985 Aug;132(2):272–277. doi: 10.1164/arrd.1985.132.2.272. [DOI] [PubMed] [Google Scholar]
  28. Sterk P. J., Timmers M. C., Dijkman J. H. Maximal airway narrowing in humans in vivo. Histamine compared with methacholine. Am Rev Respir Dis. 1986 Oct;134(4):714–718. doi: 10.1164/arrd.1986.134.4.714. [DOI] [PubMed] [Google Scholar]
  29. Tattersfield A. E. Effect of beta-agonists and anticholinergic drugs on bronchial reactivity. Am Rev Respir Dis. 1987 Oct;136(4 Pt 2):S64–S68. doi: 10.1164/ajrccm/136.4_Pt_2.S64. [DOI] [PubMed] [Google Scholar]
  30. Toogood J. H. Risk of anaphylaxis in patients receiving beta-blocker drugs. J Allergy Clin Immunol. 1988 Jan;81(1):1–5. doi: 10.1016/0091-6749(88)90212-6. [DOI] [PubMed] [Google Scholar]
  31. Woolcock A. J., Salome C. M., Yan K. The shape of the dose-response curve to histamine in asthmatic and normal subjects. Am Rev Respir Dis. 1984 Jul;130(1):71–75. doi: 10.1164/arrd.1984.130.1.71. [DOI] [PubMed] [Google Scholar]
  32. Yan K., Salome C. M., Woolcock A. J. Prevalence and nature of bronchial hyperresponsiveness in subjects with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985 Jul;132(1):25–29. doi: 10.1164/arrd.1985.132.1.25. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES